DexCom revenue and financials
$83.39Change from previous close: −4.04%Absolute change: −$3.51
In the fiscal year ended December 2025, DexCom reported revenue of $4.66B (+15.60% year over year). Net income was $836.3M, a net margin of 17.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +15.60%
- 2025 vs 2024
- Net income growth
- +45.14%
- 2025 vs 2024
- Net margin
- 17.9%
- 2024: 14.3%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 269 | 526 | 294 | 660 | 303 | 184 | 301 | 200 | 279 | 209 | 134 | 269 |
| Depreciation and amortization | 68.2 | 67.1 | 81.9 | 63.6 | 63.0 | 60.0 | 74.5 | 55.3 | 52.1 | 52.5 | 69.0 | 48.2 |
| Capital expenditure | -84.7 | -76.6 | -102 | -80.5 | -94.1 | -87.0 | -125 | -111 | -66.1 | -56.9 | -52.5 | -50.4 |
| Investing cash flow | 330 | -299 | 307 | 193 | -63.6 | 100 | -304 | 210 | -189 | 74.8 | 415 | -180 |
| Financing cash flow | -607 | -25.0 | -1,522 | -175 | -1.7 | 12.5 | -1.6 | -737 | -1.4 | 4.7 | -632 | -637 |
| Share repurchases | -605 | -35.8 | -313 | -187 | — | — | — | -750 | — | — | -500 | — |
| Debt repaid | — | — | -1,208 | — | — | — | — | — | — | — | -137 | -651 |
| Effect of exchange rates | -4.9 | -2.8 | 3.8 | -1.1 | 16.5 | 2.3 | -11.2 | 8.6 | -1.0 | -3.8 | 6.1 | -3.5 |
| Net change in cash | -13.2 | 199 | -918 | 677 | 254 | 299 | -15.1 | -318 | 88.1 | 285 | -77.3 | -551 |
| Free cash flow | 185 | 449 | 192 | 579 | 209 | 96.8 | 177 | 88.3 | 213 | 152 | 81.1 | 219 |
| Levered free cash flow | 130 | 399 | 85.8 | 407 | 166 | 61.5 | 150 | 48.4 | 250 | 112 | -56.3 | 330 |